Psychotropic drugs and diabetes

被引：6
作者：
Ress C. [1 ]
Tschoner A. [1 ]
Kaser S. [1 ]
Ebenbichler C.F. [1 ]
机构：
[1] Department für Innere Medizin i, Medizinische Universität Innsbruck, 6020 Innsbruck
来源：
Wiener Medizinische Wochenschrift | 2011年 / 161卷 / 21-22期
关键词：
Antidepressants; Antipsychotics; Diabetes; Metabolic side effects; Weight gain;
D O I：
10.1007/s10354-011-0004-9
中图分类号：
学科分类号：
摘要：
Psychotropic drugs, such as antipsychotics and antidepressants, are widely used substances which can display marked metabolic side effects. Psychiatric patients display increased morbidity and mortality which, besides disease specific factors, may be attributed to metabolic side effects of psychotropic drugs. Commonly observed side effects of antipsychotics are weight gain as well as disturbances in glucose and lipid metabolism. Additionally, antipsychotics have been shown to increase diabetes risk. Also, the use of some of the antidepressant substances is associated with an increased diabetes risk. However, large inter-substance variations have been observed. Conversely, diabetics have an increased risk of depression. Metabolic side effects of psychotropic drugs pose a serious impairment for psychiatric patients and their management can play a pivotal role in therapeutic compliance and success. This review aims to give an overview of metabolic side effects of commonly used psychotic drugs and to give an insight into possible underlying mechanisms. © 2011 Springer-Verlag.
引用
收藏
页码：531 / 542
页数：11
相关论文
共 110 条
[1]  
Newcomer J.W., Hennekens C.H., Severe mental illness and risk of cardiovascular disease, Journal of the American Medical Association, 298, 15, pp. 1794-1796, (2007)
[2]  
Roick C., Fritz-Wieacker A., Matschinger H., Heider D., Schindler J., Riedel-Heller S., Angermeyer M.C., Health habits of patients with schizophrenia, Social Psychiatry and Psychiatric Epidemiology, 42, 4, pp. 268-276, (2007)
[3]  
Lindamer L.A., McKibbin C., Norman G.J., Et al., Assessment of physical activity in middle-aged and older adults with schizophrenia, Schizophr Res, 104, pp. 294-301, (2008)
[4]  
Gracious B.L., Cook S.R., Meyer A.E., Et al., Prevalence of overweight and obesity in adolescents with severe mental illness: A cross-sectional chart review, J Clin Psychiatry, 71, pp. 949-954, (2010)
[5]  
Sundell K.A., Gissler M., Petzold M., Et al., Antidepressant utilization patterns and mortality in Swedish men and women aged 20-34 years, Eur J Clin Pharmacol, 67, pp. 169-178, (2011)
[6]  
Jin H., Folsom D., Sasaki A., Et al., Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms, Schizophr Res, 125, pp. 295-299, (2011)
[7]  
Haslam D.W., James W.P.T., Obesity, Lancet, 366, 9492, pp. 1197-1209, (2005)
[8]  
Tschoner A., Engl J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., Patsch J.R., Ebenbichler C.F., Metabolic side effects of antipsychotic medication, International Journal of Clinical Practice, 61, 8, pp. 1356-1370, (2007)
[9]  
Smith M., Hopkins D., Peveler R.C., Holt R.I.G., Woodward M., Ismail K., First- V. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis, British Journal of Psychiatry, 192, 6, pp. 406-411, (2008)
[10]  
Rouillon F., Sorbara F., Schizophrenia and diabetes: Epidemiological data, Eur Psychiatry, 20, SUPPL. 4, (2005)
12345678910